A thorough analysis of the new ICH pre-clinical safety guidelines how will these influence the registration and execution of Phase I trials? presented by David Jones, Principal Scientific Officer, Medicines and Healthcare Products Regulatory Agency, MHRA
Official Website: http://www.iir-events.com/IIR-conf/LifeSciences/EventView.aspx?EventID=2005
Added by mBLAST on September 28, 2008